Charlottesville, VA –February 23, 2010 – Diffusion Pharmaceuticals LLC today announced that three separate preclinical studies testing its lead drug candidate trans sodium crocetinate, (TSC), have been published in peer-reviewed journals during the last six months. These studies demonstrate that TSC improves tissue oxygenation in hypoxic brain tumor tissue, exerts a neuroprotective effect against ischemic [...]

Scientists in Charlottesville are studying what could be a whole new approach to treating stroke—the nation’s leading cause of disability and the third leading cause of death. WVTF’s Sandy Hausman reports on the research. Listen Dr. Lee is chair of the Department of Neuroscience at the University of Virginia School of Medicine, and will present [...]

CHARLOTTESVILLE, VA – February 6, 2009 – Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs that enhance oxygen diffusion, today announced the completion of a $2.9 million private placement. The proceeds will support the company’s overall growth and clinical programs for its lead drug compound, trans sodium crocetinate (TSC). In addition, David [...]

Diffusion Pharmaceuticals LLC selected to present at 2005 Mid-Atlantic Bio, the region’s premier biotechnology forum, October 26-27 at the Ronald Reagan Building and International Trade Center in Washington, DC. Only two of the 15 presenting companies are Virginia-based. Article on PRNewswire

Charlottesville, VA — October 22, 2004 — Diffusion Pharmaceuticals LLC, an early-stage pharmaceutical company which discovers and develops novel small-molecule therapeutics, today announced its selection as one of ten finalists to present at the 2nd annual Virginia’s Technology Capital Access Forum (VTCAF) on Thursday, October 28, 2004, in Roanoke, Virginia. The two-day event at the [...]